QuantiFERON–CMV assay by chemiluminescence immunoassay: Is it more suitable for real-live monitoring of transplant patients?

• Published in: Journal of clinical virology 2024-04, Vol.171, p.105651-105651, Article 105651
• Main Authors: Fernández-Moreno, Raquel, Páez-Vega, Aurora, Rodríguez-Cano, Diego, Salinas, Ana, Rodríguez-Cantalejo, Fernando, Jurado, Aurora, Torre-Cisneros, Julián, Cantisán, Sara
• Format: Article
• Language: English
• Subjects: Agreement; CLIA (chemiluminescence assay); CMV-specific cell-mediated immunity; QuantiFERON-CMV assay; Transplantation
• ISSN: 1386-6532; 1873-5967
• DOI: 10.1016/j.jcv.2024.105651

•The QuantiFERON-CMV assay is an ELISA-based test to monitor CMV immunity.•An automated chemiluminescent immunoassay (CLIA) has been developed to measure IFNG.•CLIA and ELISA were compared for monitoring CMV immunity in transplant patients.•Both methods show substantial concordance and acceptable discrepancies.•CLIA is a good alternative for monitoring CMV-specific immunity in clinical routine. The QuantiFERONCMV (QF-CMV) assay is an interferon-gamma release assay (IGRA) used to monitor CMV-specific cell-mediated immunity (CMV-CMI) by ELISA in transplant patients. However, a chemiluminescent immunoassay (CLIA) has been developed to quantify IFNG in the QuantiFERON-Tuberculosis (TB) to detect latent TB infection. The aim of this work is to compare the results of QF-CMV by ELISA with those obtained by CLIA in an automated Liaison XL analyzer using the QuantiFERON-TB Gold Plus reagents. The QF-CMV assay had been performed by ELISA in kidney and lung transplant patients between July 2019-April 2023 at the IMIBIC/Reina Sofía Hospital (Cordoba, Spain). The remaining QF-CMV supernatants had been preserved at -80 ºC from then. Now, the IFNG levels in the same samples were determined by CLIA. One hundred and three QF-CMV supernatants from kidney (n = 50) and lung (n = 53) transplant patients were selected. An agreement of 87.4 % (kappa coefficient 0.788) between CLIA and ELISA was observed. Thirteen (12.6 %) discrepant results were detected. Some Indeterminate results by ELISA converted to Non-reactive by CLIA (0.53–0.92 IU/mL for Mitogen-Nil values). Likewise, borderline Non-reactive results by ELISA were above the 0.2 IU/mL cut-off by CLIA and then were Reactive (0.21–0.31 for CMV-Nil values). CLIA shows substantial concordance with ELISA and acceptable discrepancies. The possible higher sensitivity of CLIA returns a higher number of Reactive results, which entails potential clinical consequences. Therefore, a new threshold to confer protection against CMV infection after transplantation needs to be defined.